KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Issued
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization (2016 - 2025)

Regeneron Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $364.8 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $364.8 million for Q4 2025, up 3.02% from a year ago — trailing twelve months through Dec 2025 was $364.8 million (up 3.02% YoY), and the annual figure for FY2025 was $364.8 million, up 3.02%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $364.8 million at Regeneron Pharmaceuticals, up from $354.1 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for REGN hit a ceiling of $421.0 million in Q4 2023 and a floor of $286.2 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $354.1 million (2024), compared with a mean of $346.0 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 38.53% in 2023 and later fell 15.89% in 2024.
  • Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization stood at $286.2 million in 2021, then increased by 6.18% to $303.9 million in 2022, then soared by 38.53% to $421.0 million in 2023, then fell by 15.89% to $354.1 million in 2024, then grew by 3.02% to $364.8 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $364.8 million (Q4 2025), $354.1 million (Q4 2024), and $421.0 million (Q4 2023) per Business Quant data.